All patients
Age < 65y (younger) Age > 75y (older) cell type, non squamous cell cell type, squamous cell ECOG 0 ECOG 1 Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES PD-L1 < 1% PD-L1 < 10% PD-L1 < 5% PD-L1 > 1% PD-L1 > 10% PD-L1 > 5% smoker (current or former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
metastatic/advanced NSCLC (mNSCLC) - 2nd line (L2), nivolumab based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 017, 2015 0.59 [0.44; 0.79]
CheckMate 057, 2015 0.73 [0.59; 0.90]
CheckMate 078, 2019 0.68 [0.52; 0.89]
0.68 [0.59 ; 0.79 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,358 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 017, 2015 0.31 [0.14; 0.69]
CheckMate 078, 2019 0.75 [0.61; 0.93]
0.53 [0.22 ; 1.23 ] CheckMate 017, 2015, CheckMate 078, 2019 2 77% 776 moderate not evaluable PFS (extension)detailed results CheckMate 017, 2015 0.48 [0.24; 0.96]
CheckMate 078, 2019 0.79 [0.64; 0.97]
0.69 [0.44 ; 1.07 ] CheckMate 017, 2015, CheckMate 078, 2019 2 46% 776 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 017, 2015 0.62 [0.47; 0.81]
CheckMate 057, 2015 0.92 [0.77; 1.10]
CheckMate 078, 2019 0.77 [0.62; 0.95]
0.77 [0.62 ; 0.96 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 66% 1,358 moderate not evaluable objective responses (ORR)detailed results CheckMate 017, 2015 2.60 [1.26; 5.35]
CheckMate 057, 2015 1.70 [1.11; 2.61]
CheckMate 078, 2019 4.40 [1.99; 9.74]
2.48 [1.43 ; 4.31 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 56% 1,358 moderate not evaluable objective responses (ORR) (extension)detailed results CheckMate 017, 2015 0.53 [0.19; 1.48]
CheckMate 078, 2019 4.80 [2.14; 10.77]
1.63 [0.19 ; 14.17 ] CheckMate 017, 2015, CheckMate 078, 2019 2 91% 776 moderate not evaluable AE (any grade)detailed results CheckMate 057, 2015 0.31 [0.20; 0.48]
0.31 [0.20 ; 0.48 ] CheckMate 057, 2015 1 0% 555 NA not evaluable AE (grade 3-4)detailed results CheckMate 057, 2015 0.42 [0.29; 0.59]
0.42 [0.29 ; 0.59 ] CheckMate 057, 2015 1 0% 555 NA not evaluable SAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.03; 0.33]
0.10 [0.03 ; 0.33 ] CheckMate 017, 2015 1 0% 260 NA not evaluable STRAE (any grade)detailed results CheckMate 017, 2015 0.23 [0.11; 0.51]
CheckMate 057, 2015 0.32 [0.19; 0.55]
CheckMate 078, 2019 0.59 [0.34; 1.02]
0.37 [0.22 ; 0.62 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 53% 1,308 moderate not evaluable STRAE (grade 3-4)detailed results CheckMate 057, 2015 0.25 [0.14; 0.46]
CheckMate 078, 2019 0.34 [0.18; 0.66]
0.29 [0.19 ; 0.45 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable TRAE (any grade)detailed results CheckMate 017, 2015 0.22 [0.12; 0.41]
CheckMate 078, 2019 0.35 [0.22; 0.57]
0.29 [0.19 ; 0.46 ] CheckMate 017, 2015, CheckMate 078, 2019 2 25% 753 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.06 [0.03; 0.13]
CheckMate 057, 2015 0.10 [0.06; 0.16]
CheckMate 078, 2019 0.15 [0.10; 0.24]
0.10 [0.07 ; 0.17 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 57% 1,308 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 078, 2019 0.61 [0.14; 2.77]
0.47 [0.12 ; 1.80 ] CheckMate 017, 2015, CheckMate 078, 2019 2 0% 753 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 017, 2015 0.28 [0.09; 0.89]
CheckMate 078, 2019 0.66 [0.32; 1.37]
0.48 [0.22 ; 1.08 ] CheckMate 017, 2015, CheckMate 078, 2019 2 33% 753 moderate not evaluable TRAE leading to discontinuation (grade 3-4)detailed results CheckMate 017, 2015 0.23 [0.05; 1.13]
CheckMate 078, 2019 0.80 [0.33; 1.95]
0.52 [0.16 ; 1.64 ] CheckMate 017, 2015, CheckMate 078, 2019 2 44% 753 moderate not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
0.49 [0.02 ; 14.75 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Alopecia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.58 [0.07 ; 5.02 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.12 [0.01; 2.29]
CheckMate 057, 2015 0.13 [0.02; 1.07]
CheckMate 078, 2019 0.15 [0.02; 1.47]
0.14 [0.03 ; 0.53 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.10 [0.01; 1.76]
CheckMate 057, 2015 0.15 [0.02; 1.28]
0.13 [0.02 ; 0.72 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.01; 23.40]
1.03 [0.08 ; 13.41 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Constipation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.23 [0.01; 5.17]
0.40 [0.04 ; 4.62 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.06; 15.91]
CheckMate 057, 2015 0.15 [0.01; 3.09]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.43 [0.07 ; 2.61 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 057, 2015 0.62 [0.10; 3.74]
CheckMate 078, 2019 0.93 [0.03; 27.74]
0.49 [0.12 ; 2.01 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Dizziness TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
0.98 [0.02 ; 50.00 ] CheckMate 017, 2015 1 0% 260 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.09 [0.01; 0.73]
CheckMate 057, 2015 0.21 [0.06; 0.74]
CheckMate 078, 2019 0.27 [0.06; 1.15]
0.20 [0.08 ; 0.47 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.03 [0.00; 0.58]
CheckMate 057, 2015 0.02 [0.00; 0.27]
0.02 [0.00 ; 0.17 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.93 [0.03; 27.74]
0.93 [0.03 ; 27.74 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 1.39 [0.14; 13.49]
1.39 [0.14 ; 13.49 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Hypersensitivity TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.23 [0.01; 6.90]
0.42 [0.03 ; 5.48 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 0.46 [0.03; 7.42]
0.81 [0.09 ; 6.95 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.03; 7.42]
0.46 [0.05 ; 3.98 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Increased lacrimation (TRAE grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.47 [0.02; 13.95]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.04 ; 6.06 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Leucopenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.19 [0.02; 1.66]
CheckMate 057, 2015 0.02 [0.00; 0.32]
CheckMate 078, 2019 0.02 [0.00; 0.18]
0.05 [0.01 ; 0.21 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 16% 1,308 moderate not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.09 [0.00; 1.69]
0.21 [0.02 ; 2.21 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 1.87 [0.06; 55.99]
1.42 [0.11 ; 18.57 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 057, 2015 0.93 [0.13; 6.67]
0.64 [0.12 ; 3.35 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Neutropenia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.01 [0.00; 0.15]
CheckMate 057, 2015 0.00 [0.00; 0.08]
CheckMate 078, 2019 0.03 [0.01; 0.15]
0.02 [0.01 ; 0.06 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.96 [0.06 ; 15.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.16 [0.01; 3.24]
CheckMate 057, 2015 0.15 [0.01; 3.09]
0.16 [0.02 ; 1.32 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Peripheral oedema TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.98 [0.02; 50.00]
CheckMate 057, 2015 0.47 [0.02; 13.95]
0.64 [0.05 ; 8.39 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Pneumonitis TRAE (grade 3-4)detailed results CheckMate 017, 2015 1.98 [0.07; 59.45]
CheckMate 057, 2015 2.82 [0.29; 27.28]
CheckMate 078, 2019 3.74 [0.20; 71.10]
2.83 [0.58 ; 13.89 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Pyrexia TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.65 [0.05 ; 8.46 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.24 [0.01; 5.45]
CheckMate 057, 2015 1.87 [0.06; 55.99]
CheckMate 078, 2019 2.79 [0.14; 56.11]
1.08 [0.17 ; 6.66 ] CheckMate 017, 2015, CheckMate 057, 2015, CheckMate 078, 2019 3 0% 1,308 moderate not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 6.60 [0.37; 116.99]
6.60 [0.37 ; 116.99 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 078, 2019 2.79 [0.14; 56.11]
2.79 [0.14 ; 56.11 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.23 [0.01; 5.17]
0.23 [0.01 ; 5.17 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
CheckMate 078, 2019 0.46 [0.01; 23.40]
0.66 [0.04 ; 10.53 ] CheckMate 057, 2015, CheckMate 078, 2019 2 0% 1,048 moderate not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 078, 2019 0.46 [0.01; 23.40]
0.46 [0.01 ; 23.40 ] CheckMate 078, 2019 1 0% 493 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 017, 2015 0.49 [0.02; 14.75]
CheckMate 057, 2015 0.93 [0.02; 47.22]
0.65 [0.05 ; 8.46 ] CheckMate 017, 2015, CheckMate 057, 2015 2 0% 815 moderate not evaluable Abdominal pain AE (grade 3-4)detailed results CheckMate 057, 2015 0.15 [0.01; 3.09]
0.15 [0.01 ; 3.09 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Alopecia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Anaemia AE (grade 3-4)detailed results CheckMate 057, 2015 0.38 [0.13; 1.09]
0.38 [0.13 ; 1.09 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Arthralgia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.13; 6.67]
0.93 [0.13 ; 6.67 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Asthenia AE (grade 3-4)detailed results CheckMate 057, 2015 0.84 [0.35; 2.02]
0.84 [0.35 ; 2.02 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Back pain AE (grade 3-4)detailed results CheckMate 057, 2015 2.36 [0.45; 12.26]
2.36 [0.45 ; 12.26 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Constipation AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.13; 6.67]
0.93 [0.13 ; 6.67 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Cough AE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
1.87 [0.06 ; 55.99 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Decreased appetite AE (grade 3-4)detailed results CheckMate 057, 2015 1.17 [0.31; 4.40]
1.17 [0.31 ; 4.40 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.19; 4.66]
0.93 [0.19 ; 4.66 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dizziness AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.06; 15.00]
0.93 [0.06 ; 15.00 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dry skin AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dysgeusia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CheckMate 057, 2015 1.32 [0.58; 3.03]
1.32 [0.58 ; 3.03 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Erythema AE (grade 3-4)detailed results CheckMate 057, 2015 0.47 [0.02; 13.95]
0.47 [0.02 ; 13.95 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Fatigue AE (grade 3-4)detailed results CheckMate 057, 2015 0.45 [0.20; 1.02]
0.45 [0.20 ; 1.02 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Febrile neutropenia AE (grade 3-4)detailed results CheckMate 057, 2015 0.01 [0.00; 0.24]
0.01 [0.00 ; 0.24 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Headache AE (grade 3-4)detailed results CheckMate 057, 2015 3.75 [0.17; 83.63]
3.75 [0.17 ; 83.63 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Increased ALT AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.06; 15.00]
0.93 [0.06 ; 15.00 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Lacrimation increased AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Leucopenia AE (grade 3-4)detailed results CheckMate 057, 2015 0.02 [0.00; 0.31]
0.02 [0.00 ; 0.31 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Mucosal inflammation AE (grade 3-4)detailed results CheckMate 057, 2015 0.18 [0.02; 1.58]
0.18 [0.02 ; 1.58 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Myalgia AE (grade 3-4)detailed results CheckMate 057, 2015 1.87 [0.06; 55.99]
1.87 [0.06 ; 55.99 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Nausea AE (grade 3-4)detailed results CheckMate 057, 2015 2.36 [0.45; 12.26]
2.36 [0.45 ; 12.26 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Neutropenia AE (grade 3-4)detailed results Out of scale CheckMate 057, 2015 0.01 [0.00; 0.07]
0.01 [0.00 ; 0.07 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Oropharyngeal pain AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Paraesthesia AE (grade 3-4)detailed results CheckMate 057, 2015 0.93 [0.02; 47.22]
0.93 [0.02 ; 47.22 ] CheckMate 057, 2015 1 0% 555 NA not evaluable Peripheral neuropathy AE (grade 3-4)detailed results CheckMate 057, 2015 0.15 [0.01; 3.09]
0.15 [0.01 ; 3.09 ] CheckMate 057, 2015 1 0% 555 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-03 18:58 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 197,255,37,245,204,244,241,227,217,177,279,167,1,170,261,280,168,169
- treatments: 855,360,719,721,720,842,642,674,1085,863
